Vessel pericytes NO-sGC signaling in COVID-19

Lead Investigator: Junhao Hu, Chinese Academy of Science
Title of Proposal Research: Vessel pericytes NO-sGC signaling in COVID-19
Vivli Data Request: 5901
Funding Source: None
Potential Conflicts of Interest: None

Summary of the Proposed Research:

Previously we found NO-sGC signaling was dramatically decreased on LPS induced Acute Respiratory Distress Syndrome (ARDS) model. Further using clinal drug Riociguat, a sGC activator, can efficient improve the lung leakage symptom. And we also found sGC was highly specifically expressed in vessel pericytes, which was a overlooked cell type in various diseases (lung/liver fibrosis).

Considering the ARDS induced by recent emerging COVID-19, we were wondering if sGC signaling decreased in this process. And if it was, can targeting lung pericytes sGC signaling improve COVID-19 survival rate.

Statistical Analysis Plan:

We will analyze the differential expressed genes between COVID-19 infected lungs and control to see if sGC genes show some different expression.

Requested Studies:

COVID-19: Pulmonary Vascular Endothelialitis, Thrombosis and Angiogenesis
Sponsor: Hannover Medical School

Summary of Results:

The research team were unable to include the data received through the data request “Vessel pericytes NO-sGC signaling in COVID-19” due to their inability to retrieve any endothelial cell or pericyte-specific information from the whole lung lysate sequencing data received.